Annual CFF
-$1.36 M
+$12.67 M+90.28%
31 December 2023
Summary:
Co-Diagnostics annual cash flow from financing activities is currently -$1.36 million, with the most recent change of +$12.67 million (+90.28%) on 31 December 2023. During the last 3 years, it has fallen by -$21.11 million (-106.91%). CODX annual CFF is now -106.91% below its all-time high of $19.74 million, reached on 31 December 2020.CODX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$0.00
$0.000.00%
30 September 2024
Summary:
Co-Diagnostics quarterly cash flow from financing activities is currently $0.00, unchanged on 30 September 2024. Over the past year, it has increased by +$166.30 thousand (+100.00%). CODX quarterly CFF is now -100.00% below its all-time high of $18.06 million, reached on 31 March 2020.CODX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$159.70 K
+$166.30 K+51.01%
30 September 2024
Summary:
Co-Diagnostics TTM cash flow from financing activities is currently -$159.70 thousand, with the most recent change of +$166.30 thousand (+51.01%) on 30 September 2024. Over the past year, it has increased by +$2.26 million (+93.41%). CODX TTM CFF is now -100.81% below its all-time high of $19.74 million, reached on 31 December 2020.CODX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CODX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +90.3% | +100.0% | +93.4% |
| 3 y3 years | -106.9% | -100.0% | -116.1% |
| 5 y5 years | -172.7% | 0.0% | -102.7% |
CODX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -106.9% | +90.3% | -100.0% | +100.0% | -116.1% | +98.9% |
| 5 y | 5 years | -106.9% | +90.3% | -100.0% | +100.0% | -100.8% | +98.9% |
| alltime | all time | -106.9% | +90.3% | -100.0% | +100.0% | -100.8% | +98.9% |
Co-Diagnostics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $0.00(0.0%) | -$159.70 K(-51.0%) |
| June 2024 | - | $0.00(0.0%) | -$326.00 K(-63.0%) |
| Mar 2024 | - | $0.00(-100.0%) | -$881.70 K(-35.4%) |
| Dec 2023 | -$1.36 M(-90.3%) | -$159.70 K(-4.0%) | -$1.36 M(-43.7%) |
| Sept 2023 | - | -$166.30 K(-70.1%) | -$2.42 M(-80.9%) |
| June 2023 | - | -$555.70 K(+15.2%) | -$12.65 M(-13.7%) |
| Mar 2023 | - | -$482.20 K(-60.4%) | -$14.67 M(+4.5%) |
| Dec 2022 | -$14.03 M(-3215.9%) | -$1.22 M(-88.3%) | -$14.03 M(+9.5%) |
| Sept 2022 | - | -$10.39 M(+304.2%) | -$12.82 M(+430.5%) |
| June 2022 | - | -$2.57 M(-1814.4%) | -$2.42 M(-635.2%) |
| Mar 2022 | - | $150.00 K(>+9900.0%) | $451.40 K(+0.2%) |
| Dec 2021 | $450.40 K(-97.7%) | $0.00(-100.0%) | $450.40 K(-54.6%) |
| Sept 2021 | - | $5500.00(-98.1%) | $993.00 K(-21.3%) |
| June 2021 | - | $295.90 K(+98.6%) | $1.26 M(-31.0%) |
| Mar 2021 | - | $149.00 K(-72.5%) | $1.83 M(-90.7%) |
| Dec 2020 | $19.74 M | $542.60 K(+97.7%) | $19.74 M(+2.8%) |
| Sept 2020 | - | $274.50 K(-68.2%) | $19.20 M(+1.5%) |
| June 2020 | - | $863.50 K(-95.2%) | $18.93 M(+4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $18.06 M(>+9900.0%) | $18.06 M(+206.0%) |
| Dec 2019 | $5.90 M(+214.6%) | $0.00(0.0%) | $5.90 M(+0.4%) |
| Sept 2019 | - | $0.00(0.0%) | $5.88 M(-24.4%) |
| June 2019 | - | $0.00(-100.0%) | $7.78 M(0.0%) |
| Mar 2019 | - | $5.90 M(<-9900.0%) | $7.78 M(+314.7%) |
| Dec 2018 | $1.88 M(-68.4%) | -$22.90 K(-101.2%) | $1.88 M(-1.2%) |
| Sept 2018 | - | $1.90 M(>+9900.0%) | $1.90 M(-68.7%) |
| June 2018 | - | $0.00(0.0%) | $6.06 M(+1.4%) |
| Mar 2018 | - | $0.00(0.0%) | $5.98 M(+0.7%) |
| Dec 2017 | $5.94 M(+159.3%) | $0.00(-100.0%) | $5.94 M(-20.2%) |
| Sept 2017 | - | $6.06 M(-7208.1%) | $7.44 M(+330.4%) |
| June 2017 | - | -$85.30 K(+105.5%) | $1.73 M(-14.7%) |
| Mar 2017 | - | -$41.50 K(-102.8%) | $2.03 M(-11.4%) |
| Dec 2016 | $2.29 M(+56.8%) | $1.51 M(+330.3%) | $2.29 M(+192.2%) |
| Sept 2016 | - | $350.00 K(+63.9%) | $783.50 K(+80.7%) |
| June 2016 | - | $213.50 K(-3.0%) | $433.50 K(+97.0%) |
| Mar 2016 | - | $220.00 K | $220.00 K |
| Dec 2015 | $1.46 M | - | - |
FAQ
- What is Co-Diagnostics annual cash flow from financing activities?
- What is the all time high annual CFF for Co-Diagnostics?
- What is Co-Diagnostics annual CFF year-on-year change?
- What is Co-Diagnostics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Co-Diagnostics?
- What is Co-Diagnostics quarterly CFF year-on-year change?
- What is Co-Diagnostics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Co-Diagnostics?
- What is Co-Diagnostics TTM CFF year-on-year change?
What is Co-Diagnostics annual cash flow from financing activities?
The current annual CFF of CODX is -$1.36 M
What is the all time high annual CFF for Co-Diagnostics?
Co-Diagnostics all-time high annual cash flow from financing activities is $19.74 M
What is Co-Diagnostics annual CFF year-on-year change?
Over the past year, CODX annual cash flow from financing activities has changed by +$12.67 M (+90.28%)
What is Co-Diagnostics quarterly cash flow from financing activities?
The current quarterly CFF of CODX is $0.00
What is the all time high quarterly CFF for Co-Diagnostics?
Co-Diagnostics all-time high quarterly cash flow from financing activities is $18.06 M
What is Co-Diagnostics quarterly CFF year-on-year change?
Over the past year, CODX quarterly cash flow from financing activities has changed by +$166.30 K (+100.00%)
What is Co-Diagnostics TTM cash flow from financing activities?
The current TTM CFF of CODX is -$159.70 K
What is the all time high TTM CFF for Co-Diagnostics?
Co-Diagnostics all-time high TTM cash flow from financing activities is $19.74 M
What is Co-Diagnostics TTM CFF year-on-year change?
Over the past year, CODX TTM cash flow from financing activities has changed by +$2.26 M (+93.41%)